vs
BIOMERICA INC（BMRA）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是BIOMERICA INC的578.4倍（$699.9M vs $1.2M）。QuidelOrtho Corp净利率更高（-104.7% vs -109.1%，领先4.4%）。QuidelOrtho Corp同比增速更快（-3.7% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs -2.9%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
BMRA vs QDEL — 直观对比
营收规模更大
QDEL
是对方的578.4倍
$1.2M
营收增速更快
QDEL
高出22.3%
-26.0%
净利率更高
QDEL
高出4.4%
-109.1%
两年增速更快
BMRA
近两年复合增速
-2.9%
损益表 — Q2 2026 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $699.9M |
| 净利润 | $-1.3M | $-733.0M |
| 毛利率 | 4.2% | — |
| 营业利润率 | -113.5% | -100.7% |
| 净利率 | -109.1% | -104.7% |
| 营收同比 | -26.0% | -3.7% |
| 净利润同比 | -38.9% | -3583.4% |
| 每股收益（稀释后） | $-0.45 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRAQDEL
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | $699.9M | ||
| Q2 25 | $749.0K | $613.9M | ||
| Q1 25 | $1.1M | $692.8M | ||
| Q4 24 | $1.6M | $707.8M | ||
| Q3 24 | $1.8M | $727.1M | ||
| Q2 24 | $1.1M | $637.0M | ||
| Q1 24 | $1.0M | $711.0M |
净利润BMRAQDEL
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | $-733.0M | ||
| Q2 25 | $-1.5M | $-255.4M | ||
| Q1 25 | $-1.2M | $-12.7M | ||
| Q4 24 | $-950.0K | $-178.4M | ||
| Q3 24 | $-1.3M | $-19.9M | ||
| Q2 24 | $-1.4M | $-147.7M | ||
| Q1 24 | $-1.9M | $-1.7B |
毛利率BMRAQDEL
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
营业利润率BMRAQDEL
| Q4 25 | -113.5% | — | ||
| Q3 25 | -81.0% | -100.7% | ||
| Q2 25 | -209.1% | -29.4% | ||
| Q1 25 | -108.1% | 4.7% | ||
| Q4 24 | -60.7% | -14.2% | ||
| Q3 24 | -75.7% | 2.1% | ||
| Q2 24 | -136.6% | -18.4% | ||
| Q1 24 | -196.7% | -247.3% |
净利率BMRAQDEL
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | -104.7% | ||
| Q2 25 | -206.1% | -41.6% | ||
| Q1 25 | -103.9% | -1.8% | ||
| Q4 24 | -58.1% | -25.2% | ||
| Q3 24 | -72.8% | -2.7% | ||
| Q2 24 | -127.1% | -23.2% | ||
| Q1 24 | -188.6% | -239.9% |
每股收益（稀释后）BMRAQDEL
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | $-10.78 | ||
| Q2 25 | $-0.99 | $-3.77 | ||
| Q1 25 | $-0.48 | $-0.19 | ||
| Q4 24 | $-0.06 | $-2.54 | ||
| Q3 24 | $-0.63 | $-0.30 | ||
| Q2 24 | $-2.57 | $-2.20 | ||
| Q1 24 | $-0.11 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $98.1M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $4.4M | $2.0B |
| 总资产 | $6.0M | $5.7B |
| 负债/权益比越低杠杆越低 | — | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资BMRAQDEL
| Q4 25 | $2.5M | — | ||
| Q3 25 | $3.1M | $98.1M | ||
| Q2 25 | $3.1M | $151.7M | ||
| Q1 25 | $3.1M | $127.1M | ||
| Q4 24 | $2.4M | $98.3M | ||
| Q3 24 | $2.8M | $143.7M | ||
| Q2 24 | $4.2M | $107.0M | ||
| Q1 24 | $5.3M | $78.5M |
总债务BMRAQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益BMRAQDEL
| Q4 25 | $4.4M | — | ||
| Q3 25 | $5.2M | $2.0B | ||
| Q2 25 | $4.1M | $2.8B | ||
| Q1 25 | $5.5M | $3.0B | ||
| Q4 24 | $5.1M | $3.0B | ||
| Q3 24 | $5.3M | $3.2B | ||
| Q2 24 | $6.6M | $3.2B | ||
| Q1 24 | $7.8M | $3.3B |
总资产BMRAQDEL
| Q4 25 | $6.0M | — | ||
| Q3 25 | $6.9M | $5.7B | ||
| Q2 25 | $5.9M | $6.4B | ||
| Q1 25 | $7.4M | $6.5B | ||
| Q4 24 | $7.3M | $6.4B | ||
| Q3 24 | $7.9M | $6.8B | ||
| Q2 24 | $9.3M | $6.7B | ||
| Q1 24 | $10.3M | $6.7B |
负债/权益比BMRAQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-94.7M |
| 自由现金流率自由现金流/营收 | — | -13.5% |
| 资本支出强度资本支出/营收 | — | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-153.1M |
8季度趋势，按日历期对齐
经营现金流BMRAQDEL
| Q4 25 | $-991.0K | — | ||
| Q3 25 | $-268.0K | $-45.5M | ||
| Q2 25 | $-661.0K | $-46.8M | ||
| Q1 25 | $-1.0M | $65.6M | ||
| Q4 24 | $-791.0K | $63.7M | ||
| Q3 24 | $-1.3M | $117.9M | ||
| Q2 24 | $-1.0M | $-97.9M | ||
| Q1 24 | $-1.8M | $-700.0K |
自由现金流BMRAQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | $-1.1M | $-133.2M | ||
| Q1 24 | — | $-66.8M |
自由现金流率BMRAQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | -95.5% | -20.9% | ||
| Q1 24 | — | -9.4% |
资本支出强度BMRAQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | 2.1% | 5.5% | ||
| Q1 24 | 0.0% | 9.3% |
现金转化率BMRAQDEL
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRA
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
